Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-11
2011-01-11
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S296000
Reexamination Certificate
active
07868012
ABSTRACT:
The invention relates to novel sulfamic acid amides and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists.
REFERENCES:
patent: 0 526 708 (1993-02-01), None
patent: 0 743 307 (1996-11-01), None
patent: 0 658 548 (1997-11-01), None
patent: 0 882 719 (1998-12-01), None
patent: 0 633 259 (1999-01-01), None
patent: 0 959 072 (1999-11-01), None
patent: WO-96/19459 (1996-06-01), None
patent: WO-02/053557 (2002-07-01), None
patent: WO-2004/050640 (2004-06-01), None
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Morimoto, H., et al.; “Potent and Selective ET-A Antagonists. 2. Discovery and Evaluation of Potent and Water SolubleN-(6-(2-(Aryloxy)ethoxy)-4-pyrimidinyl)sulfonamide Derivatives”; J. Med. Chem. 2001, vol. 44, pp. 3369-3377.
Yanagisawa, M., et al.; “A novel potent vasoconstrictor peptide produced by vascular endothelial cells”; Nature, vol. 332, Mar. 1988, pp. 411-415.
McMillen, M. et al.; “Endothelins: Polyfunctional Cytokines”; Journal of the American College of Surgeons, vol. 180, May 1995, pp. 621-637.
Rubanyi, G.M. et al.; “Endothelins: Molecular Biology, Biochemistry, Pharmacology, Physiology, and Pathophysiology”; Pharmacological Reviews, vol. 46, No. 3, 1994, pp. 328-415.
Arai, H. et al.; “Cloning and expression of a cDNA encoding and endothelin receptor”; Nature, vol. 348, 1990, pp. 730-732.
Sakurai, T. et al.; “Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor”; Nature, vol. 348, 1990, pp. 732-735.
Ohlstein E. H. et al.; “Endothelin-1 Modulates Vascular Smooth Muscle Structure and Vasomotion: Implications in Cardiovascular Pathology”; Drug Development Research, vol. 29, 1993, pp. 108-128.
Ogawa, Y. et al.; “Molecular Cloning of a Non-Isopeptide-Selective Human Endothelin Recpetor”; Biochemical and Biophysical Research Communications, vol. 178, No. 1, 1991, pp. 248-255.
Sumner, M. et al.; “Endothelin ETAand ETBreceptors mediate vascular smooth muscle contraction”; Br. J. Pharmacol, vol. 107, 1992, pp. 858-860.
Breu, V. et al.; “In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETAand ETBreceptors”; FEBS Letters, vol. 334, No. 2, 1993, pp. 210-214.
Neidhart, W. et al.; “The Discovery of Nonpeptide Endothelin Receptor Antagonists. Progression towards Bosentan”; Chimia, vol. 50, 1996, pp. 519-524.
Neidhart, W. et al.; “Discovery of RO 48-5695: A Potent Mixed Endothelin Receptor Antagonist Optimized From Bosentan”; Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 17, 1997, pp. 2223-2228.
Nugent, R. et al.; “Pyrimidine Thioethers: A Novel Class of HIV-1 Reverse Transcriptase Inhibitors with Activity Against BHAP-Resistant HIV”; Journal of Medicinal Chemistry., vol. 41, 1998, pp. 3793-3803.
Crosby, D. et al.; “n—Butyl 5-Choloro-2-pyrimidoxyacetate—A Plant Growth Regulator Analog”; J. Med. Chem. Soc., vol. 25, 1960, pp. 1916-1919.
Brown, D.J. et al.; “Pyrimidine Reactions”; Aus. J. Chem, vol. 17, 1964, pp. 794-802.
Paquette, L. et al; “The Chlorination of Conjugated Dienamides. A New Application of the Principles of Least Motion”; J. Org. Chem., vol. 32, 1967, pp. 2725-2731.
Tozer, M. et al.; “4-Chlorobenzyl Sulfonamide and Sulfamide Derivatives of Histamine Homologues: The Design of Potent Histamine H3Receptor Antagonists”; Bioorganic & Medicinal Chemistry Letters, vol. 9, 1999, pp. 3103-3108.
Dewynter, G. et al.; “Synthese de “sulfahydantoines” chirales. Aspects stereochimiques et protection regiospecifique”; Tetrahedron, vol. 49, No. 1, 1993, pp. 65-76.
Bolli Martin
Boss Christoph
Clozel Martine
Fischli Walter
Weller Thomas
Actelion Pharmaceuticals Ltd.
Hoxie & Associates LLC
Rao Deepak
LandOfFree
Sulfamides as endothelin receptor antagonists for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfamides as endothelin receptor antagonists for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfamides as endothelin receptor antagonists for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2636793